NNewLimit Team
NewLimit
Last updated: February 23, 2026
Developing epigenetic therapies to extend human healthspan by reprogramming aging cells Biotech Healthcare
Founders Fund, $130M Series B in 2025
Developing epigenetic therapies to extend human healthspan by reprogramming aging cells Biotech Healthcare
Founders Fund, $130M Series B in 2025
- Series B • Founders Fund, $130M Series B in 2025
Founder Intelligence Brief: NewLimit Team
This profile is built to help readers move from a founder name to decision-ready context. NewLimit Team is mapped to NewLimit in the Biotech category, with current stage context as Series B. The primary operating market is San Francisco Bay Area, California, USA, which connects this profile directly to regional ecosystem pages and related industry hubs.
Funding visibility currently shows $130.00M, with the latest mapped round as Series B (Founders Fund, $130M Series B in 2025). This makes it easier to evaluate growth narrative against capital stage rather than reading isolated updates without baseline context.
For deeper research, combine this founder page with the company profile, company news hub, country newsroom and Biotech startup list. This route gives a cleaner picture of execution, market demand, and competitive movement.
Research flow
- Validate company baseline on company intelligence.
- Compare market peers via Biotech industry routes and Series B stage pages.
- Track fresh updates in newsroom coverage and signals feed.
Operating context
- Geography: United States directory.
- Stage signal: Series B funding coverage.
- Hiring status: Open Roles.
Related Founders
More founders in Biotech.
Want to get featured on 100Xfounder?
Get your founder profile published with verified funding and hiring context.
Related Pillar Pages
Access the country, industry, stage, startup taxonomy, and newsroom routes connected to this founder.
FAQs About NewLimit Team
Common questions people ask about this profile.
Who is NewLimit Team?
NewLimit Team is the founder profile listed on 100Xfounder for NewLimit, tracked for market signals, company intelligence, and operator-level context.
What does NewLimit do?
Developing epigenetic therapies to extend human healthspan by reprogramming aging cells Biotech Healthcare
Where is NewLimit based?
NewLimit is listed as operating from San Francisco Bay Area, California, USA.
What is the current funding stage of NewLimit?
NewLimit is currently categorized at Series B on 100Xfounder. Funding signal: Founders Fund, $130M Series B in 2025
What is the latest funding round for NewLimit?
The latest tracked round for NewLimit is Series B Founders Fund, $130M Series B in 2025. Total tracked rounds: 1.
Is NewLimit hiring right now?
Current hiring signal for NewLimit: Open Roles.
Is NewLimit Team's profile verified?
Yes. NewLimit Team's profile is marked as verified on 100Xfounder as of March 3, 2026.
How can I connect with NewLimit Team?
You can use the profile action buttons and listed links on 100Xfounder. Contact context is provided with business relevance and profile metadata for www.newlimit.com.
What technologies are associated with NewLimit?
NewLimit is associated with AWS, React, Python, and PostgreSQL based on current profile intelligence.